ASH: Gilead preps filing for anito-cel on iMMagine-1 data Gilead's Kite unit has showcased three new CAR-T therapies at ASH, headed by multiple myeloma candidate anito-cel, which could launch next year.

#GileadSciences' #Kite unit has showcased three new #CARTtherapies at #ASH, headed by #multiplemyeloma candidate anitocabtagene autoleucel (anito-cel), which is being prepared for a filing and potential launch in 2026.

pharmaphorum.com/news/ash-gil...

FirstWord

#AbbVie #Biogen #BMS #CapstanTherapeutics #CARTtherapies #Gilead #JnJ #Novartis #ParvusTherapeutics #SAGETherapeutics #SupernusPharmaceuticals #UmojaBiopharma #4DMolecularTherapeutics #4DMT #Regeneron #Tecvayli #GSK #Dizal #UnicyciveTherapeutics #AstraZeneca
firstwordpharma.com/story/5978127

There is enough experience with the first wave of autologous #CARTtherapies targeting #CD19 and #BCMA to allow strict rules ensuring their safe use to be relaxed, according to the #FDA.

pharmaphorum.com/news/fda-loo...

The mid-March issue of The Immuno-Oncology Digest has arrived! Discover exclusive insights on next-gen #CARTtherapies, innovative research tools and honors for leading investigators: mailchi.mp/parkerici/th...

#CancerResearch #Immunotherapy #PICInetwork

CAR T for Lupus Takes Center Stage at ACR 2024 Investigational CAR T therapies stole the spotlight at the American College of Rheumatology Convergence as data presented by Bristol Myers Squibb, Kyverna Therapeutics and more highlighted their poten...

Investigational #CARTtherapies stole the spotlight at the American College of Rheumatology Convergence. Kyverna Therapeutics, Bristol Myers Squibb, Cabaletta Bio, and Fate Therapeutics Inc. all presented data. #lupus #autoimmune #celltherapy #patientaccess www.biospace.com/drug-develop...